Indian gold treating cancer in the age of nano.
Departments of Radiation, University of Pennsylvania, Philadelphia, USA. tuttle@uphs.upenn.edu
Stephen
S
Tuttle
Lauren
L
Hertan
Joshua S
JS
Katz
D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D003474:Curcumin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism; D006023:Glycoproteins / Q000235:genetics; D006801:Humans; D008527:Medulloblastoma / Q000188:drug therapy* / Q000378:metabolism; D058990:Molecular Targeted Therapy; D053769:Nanocapsules; D010455:Peptides / Q000235:genetics; D011108:Polymers; D017526:Receptor, IGF Type 1 / Q000235:genetics; D015398:Signal Transduction; D012995:Solubility; D054481:Thioredoxin Reductase 1 / Q000737:chemistry / Q000378:metabolism
D000071916:AC133 Antigen; D015703:Antigens, CD; D000970:Antineoplastic Agents; D006023:Glycoproteins; D053769:Nanocapsules; D010455:Peptides; D011108:Polymers; C516124:TXNRD1 protein, human; D054481:Thioredoxin Reductase 1; D017526:Receptor, IGF Type 1; D003474:Curcumin